"60 Degrees Pharma Celebrates First Negative Babesiosis Test in Landmark Trial"

60 Degrees Pharmaceuticals celebrates a breakthrough as the first patient in its trial for ARAKODA tests negative for Babesiosis, indicating potential progress in treating this severe infection.

• In a landmark trial, the first patient treated with Tafenoquine for relapsing Babesiosis has shown a negative test result, marking a significant milestone for the study.
• The expanded access study targets immunosuppressed patients suffering from Babesia infections who have not responded to standard treatments, highlighting the critical need for new Medication.
• Conducted under the oversight of the Food and Drug Administration, this trial aims to address the challenges of immunosuppression in patients vulnerable to Babesiosis.